In 2023, ad spend on weight-loss drugs by Novo Nordisk and Eli Lilly surged by 250% YoY in the US, with Lilly leading the increase. However, both companies have recently scaled back ad spending due to supply chain issues. Eli Lilly's new direct-to-consumer website surpassed CVS.com and Walgreens.com in user engagement. Sensor Tower data shows that Eli Lilly is more actively targeting the Hispanic community, with 33% of ads for Mounjaro in Spanish.